Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Decreases By 47.3%

by · The Cerbat Gem

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Free Report) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totaling 57,108 shares, a decrease of 47.3% from the June 30th total of 108,461 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average trading volume of 69,290 shares, the short-interest ratio is currently 0.8 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in iShares Genomics Immunology and Healthcare ETF stock. Triumph Capital Management acquired a new stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,481 shares of the company’s stock, valued at approximately $35,000.

iShares Genomics Immunology and Healthcare ETF Stock Down 1.4%

Shares of IDNA stock traded down $0.46 during mid-day trading on Friday, reaching $32.33. The stock had a trading volume of 40,633 shares, compared to its average volume of 43,186. iShares Genomics Immunology and Healthcare ETF has a one year low of $20.93 and a one year high of $34.97. The firm has a market cap of $190.75 million, a PE ratio of 14.76 and a beta of 0.92. The firm’s 50 day simple moving average is $31.64 and its 200 day simple moving average is $30.20.

iShares Genomics Immunology and Healthcare ETF Company Profile

(Get Free Report)

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.

Further Reading